OXYBUTYNIN CHLORIDE SYRUP, USP 5 mg/5 mL

Manufacturer
Morton Grove Pharmaceuticals, Inc.
Effective date
2018-12-21
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
3
Source
legacy-cache
Hydrated at
2026-08-02 00:39:42

Label at a glance#

ProductOXYBUTYNIN CHLORIDE
Active ingredientOXYBUTYNIN CHLORIDE
Label structure11 sections

Indications and uses

Oxybutynin chloride syrup is indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (ie, urgency, frequency, urinary leakage, urge incontinence, dysuria).

Dosage and administration

The usual dose is one teaspoonful (5 mg/5 mL) syrup two to three times a day. The maximum recommended dose is one teaspoonful (5 mg/5 mL) syrup four times a day. The usual dose is one teaspoonful (5 mg/5 mL) two times a day. The maximum recommended dose is one teaspoonful (5 mg/5 mL) three times a day.

Label contents#

Full prescribing information#

DESCRIPTION

DESCRIPTION SECTION

Chemically, oxybutynin chloride is 4-(Diethylamino)-2-butynyl (±)-α-phenylcyclohexaneglycolate hydrochloride. The molecular formula of oxybutynin chloride is C22H31NO3•HCl. The structural formula appears below:

DESCRIPTION
DESCRIPTION

Oxybutynin chloride is a white crystalline solid with a molecular weight of 393.96. It is readily soluble in water and acids, but relatively insoluble in alkalis.

Each 5 mL, for oral administration, contains 5 mg of oxybutynin chloride. In addition, the following inactive ingredients are present: Artificial raspberry flavor; citric acid, USP; D&C Yellow No. 10; FD&C Blue No. 1; glycerin, USP; liquid sugar; methylparaben, NF; propylene glycol, USP; sodium citrate, USP and sorbitol solution, USP.

Therapeutic Category: Antispasmodic, anticholinergic.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Oxybutynin chloride exerts direct antispasmodic effect on smooth muscle and inhibits the muscarinic action of acetylcholine on smooth muscle. Oxybutynin chloride exhibits only one fifth of the anticholinergic activity of atropine on the rabbit detrusor muscle, but four to ten times the antispasmodic activity. No blocking effects occur at skeletal neuromuscular junctions or autonomic ganglia (antinicotinic effects).

Oxybutynin chloride relaxes bladder smooth muscle. In patients with conditions characterized by involuntary bladder contractions, cystometric studies have demonstrated that oxybutynin chloride increases bladder (vesical) capacity, diminishes the frequency of uninhibited contractions of the detrusor muscle, and delays the initial desire to void. Oxybutynin chloride thus decreases urgency and the frequency of both incontinent episodes and voluntary urination.

Oxybutynin chloride was well tolerated in patients administered the drug in controlled studies of 30 days duration and in uncontrolled studies in which some patients received the drug for 2 years. Pharmacokinetic information is not currently available.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Oxybutynin chloride syrup is indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (ie, urgency, frequency, urinary leakage, urge incontinence, dysuria).

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Oxybutynin chloride is contraindicated in patients with untreated angle closure glaucoma and in patients with untreated narrow anterior chamber angles since anticholinergic drugs may aggravate these conditions.

It is also contraindicated in partial or complete obstruction of the gastrointestinal tract, paralytic ileus, intestinal atony of the elderly or debilitated patient, megacolon, toxic megacolon complicating ulcerative colitis, severe colitis, and myasthenia gravis. It is contraindicated in patients with obstructive uropathy and in patients with unstable cardiovascular status in acute hemorrhage.

Oxybutynin chloride is contraindicated in patients who have demonstrated hypersensitivity to the product.

WARNINGS

WARNINGS SECTION

Oxybutynin chloride, when administered in the presence of a high environmental temperature, can cause heat prostration (fever and heat stroke due to decreased sweating). Diarrhea may be an early symptom of incomplete intestinal obstruction, especially in patients with ileostomy, or colostomy. In this instance treatment with oxybutynin chloride would be inappropriate and possibly harmful.

Oxybutynin chloride may produce drowsiness or blurred vision. The patient should be cautioned regarding activities requiring mental alertness such as operating a motor vehicle or other machinery or performing hazardous work while taking this drug.

Alcohol or other sedative drugs may enhance the drowsiness caused by oxybutynin chloride.

PRECAUTIONS

PRECAUTIONS SECTION

Oxybutynin chloride should be used with caution in the elderly and in all patients with autonomic neuropathy, hepatic or renal disease. Oxybutynin chloride may aggravate the symptoms of hyperthyroidism, coronary heart disease, congestive heart failure, cardiac arrhythmias, hiatal hernia, tachycardia, hypertension, and prostatic hypertrophy.

Administration of oxybutynin chloride to patients with ulcerative colitis may suppress intestinal motility to the point of producing a paralytic ileus and precipitate or aggravate toxic megacolon, a serious complication of the disease.

Carcinogenesis, Mutagenesis, Impairment of Fertility

A 24-month study in rats at dosages up to approximately 400 times the recommended human dosage showed no evidence of carcinogenicity.

Oxybutynin chloride showed no increase of mutagenic activity when tested in Schizosaccharomyces pompholiciformis, Saccharomyces cerevisiae and Salmonella typhimurium test systems. Reproduction studies in the hamster, rabbit, rat, and mouse have shown no definite evidence of impaired fertility.

Pregnancy

PREGNANCY SECTION

Teratogenic Effects-Pregnancy Category B

Reproduction studies in the hamster, rabbit, rat, and mouse have shown no definite evidence of impaired fertility or harm to the animal fetus. The safety of oxybutynin chloride administered to women who are or who may become pregnant has not been established. Therefore, oxybutynin chloride should not be given to pregnant women unless, in the judgment of the physician, the probable clinical benefits outweigh the possible hazards.

Nursing Mothers

NURSING MOTHERS SECTION

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when oxybutynin chloride is administered to a nursing woman.

Pediatric Use

PEDIATRIC USE SECTION

The safety and efficacy of oxybutynin chloride administration have been demonstrated for pediatric patients 5 years of age and older (see DOSAGE AND ADMINISTRATION). However, as there is insufficient clinical data for pediatric patients under age 5, oxybutynin chloride is not recommended for this age group.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Following administration of oxybutynin chloride, the symptoms that can be associated with the use of other anticholinergic drugs may occur:

Cardiovascular: Palpitations, tachycardia, vasodilatation

Dermatologic: Decreased sweating, rash

Gastrointestinal/Genitourinary: Constipation, decreased gastrointestinal motility, dry mouth, nausea, urinary hesitance and retention

Nervous System: Asthenia, dizziness, drowsiness, hallucinations, insomnia, restlessness

Ophthalmic: Amblyopia, cycloplegia, decreased lacrimation, mydriasis

Other: Impotence, suppression of lactation

OVERDOSAGE

OVERDOSAGE SECTION

The symptoms of overdosage with oxybutynin chloride may be any of those seen with other anticholinergic agents. Symptoms may include signs of central nervous system excitation (eg, restlessness, tremor, irritability, convulsions, delirium, hallucinations), flushing, fever, nausea, vomiting, tachycardia, hypotension or hypertension, respiratory failure, paralysis, and coma. In the event of an overdose or exaggerated response, treatment should be symptomatic and supportive. Maintain respiration and induce emesis or perform gastric lavage (emesis is contraindicated in precomatose patients, convulsive or psychotic state). Activated charcoal may be administered as well as a cathartic. Physostigmine may be considered to reverse symptoms of anticholinergic intoxication. Hyperpyrexia may be treated symptomatically with ice bags or other cold applications and sponges.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

Adults

The usual dose is one teaspoonful (5 mg/5 mL) syrup two to three times a day. The maximum recommended dose is one teaspoonful (5 mg/5 mL) syrup four times a day.

Children over 5 years of age

The usual dose is one teaspoonful (5 mg/5 mL) two times a day. The maximum recommended dose is one teaspoonful (5 mg/5 mL) three times a day.

HOW SUPPLIED

HOW SUPPLIED SECTION

Oxybutynin Chloride Syrup, USP 5 mg/5 mL is a light aqua, raspberry-flavored liquid supplied in 1 Pint (473 mL) bottles.

Pharmacist: Dispense in tight, light-resistant container as defined in the USP.

Store at controlled room temperature 15° to 30°C (59° to 86°F).

Rx Only

Product No.: 8092

Manufactured By:

Morton Grove Pharmaceuticals, Inc.

Morton Grove, IL 60053

A50-8092-16

REV. 07-18

PRINCIPAL DISPLAY PANEL Bottle Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

MGP

NDC 60432-092-16

OXYBUTYNIN CHLORIDE

SYRUP, USP

5 mg/5 mL

Each teaspoonful (5 mL) contains:

5 mg oxybutynin chloride

DO NOT USE IF INNER FOIL SEAL PRINTED "SEALED

FOR YOUR PROTECTION" IS BROKEN OR MISSING.

BULK CONTAINER —

NOT FOR HOUSEHOLD USE

Rx Only

NET: 1 Pint (473 mL)

Oxybutynin Label
Oxybutynin Label

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDCEffectiveActionDocumentIndexing SPLRelated label
60432-092-162025-12-12C16284748780-1f386c649-e43d-0266-e053-dadaa90a7c1aOXYBUTYNIN CHLORIDE SYRUP, USP 5 mg/5 mL
60432-092-162023-01-30C16284748780-1f386c649-e43d-0266-e053-dadaa90a7c1aOXYBUTYNIN CHLORIDE SYRUP, USP 5 mg/5 mL

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
60432-092OXYBUTYNIN CHLORIDE SYRUP [MORTON GROVE PHARMACEUTICALS, INC.]3Legacy NDC20181222_17d61203-a462-4393-b261-72bf48d51942.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
60432-092-16ML - Milliliter60432-092ba182e47-bf32-49e0-9cb9-4fe242a1043d12013-02-13

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
Oxybutynin ChlorideACTIVE INGREDIENTL9F3D9RENQ2
OxybutyninACTIVE MOIETYK9P6MC70922
Anhydrous Citric AcidINACTIVE INGREDIENTXF417D3PSL2
D&C Yellow No. 10INACTIVE INGREDIENT35SW5USQ3G2
FD&C Blue No. 1INACTIVE INGREDIENTH3R47K3TBD2
GlycerinINACTIVE INGREDIENTPDC6A3C0OX2
MethylparabenINACTIVE INGREDIENTA2I8C7HI9T2
Propylene GlycolINACTIVE INGREDIENT6DC9Q167V32
SorbitolINACTIVE INGREDIENT506T60A25R2
SucroseINACTIVE INGREDIENTC151H8M5542
Trisodium Citrate DihydrateINACTIVE INGREDIENTB22547B95K2
WaterINACTIVE INGREDIENT059QF0KO0R2

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 12 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
60432-09260432-092-16

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 11 matching rows.

Source Document#

Source XML · Source PDF

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 9 · 503 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
Anhydrous Citric AcidANHYDROUS CITRIC ACIDXF417D3PSLSPRAY, METERED / NASAL1.2 mg/1mlExact identifier — unii candidate
61 equally ranked IID candidates
MethylparabenMETHYLPARABENA2I8C7HI9TINJECTION / SUBCUTANEOUS22 mgExact identifier — unii candidate
79 equally ranked IID candidates
Anhydrous Citric AcidANHYDROUS CITRIC ACIDXF417D3PSLINJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS414 mgExact identifier — unii candidate
61 equally ranked IID candidates
Propylene GlycolPROPYLENE GLYCOL6DC9Q167V3LOTION / TOPICAL3392 mgExact identifier — unii candidate
81 equally ranked IID candidates
Propylene GlycolPROPYLENE GLYCOL6DC9Q167V3SOLUTION / OPHTHALMIC1 %w/vExact identifier — unii candidate
81 equally ranked IID candidates
GlycerinGLYCERINPDC6A3C0OXCAPSULE, COATED / ORAL14.21 mgExact identifier — unii candidate
75 equally ranked IID candidates
Trisodium Citrate DihydrateTRISODIUM CITRATE DIHYDRATEB22547B95KSUSPENSION/ DROPS / OPHTHALMIC7 mgExact identifier — unii candidate
47 equally ranked IID candidates
GlycerinGLYCERINPDC6A3C0OXSUSPENSION/ DROPS / ORAL750 mgExact identifier — unii candidate
75 equally ranked IID candidates
Anhydrous Citric AcidANHYDROUS CITRIC ACIDXF417D3PSLFILM / SUBLINGUAL11 mgExact identifier — unii candidate
61 equally ranked IID candidates
SucroseSUCROSEC151H8M554POWDER, FOR SOLUTION / ORAL38666 mgExact identifier — unii candidate
48 equally ranked IID candidates
D&C Yellow No. 10D&C YELLOW NO. 1035SW5USQ3GPOWDER, FOR SOLUTION / ORALNAExact identifier — unii candidate
31 equally ranked IID candidates
SorbitolSORBITOL506T60A25RSYRUP / ORAL4370 mg/5mlExact identifier — unii candidate
44 equally ranked IID candidates
Anhydrous Citric AcidANHYDROUS CITRIC ACIDXF417D3PSLSOLUTION / RESPIRATORY (INHALATION)5 mgExact identifier — unii candidate
61 equally ranked IID candidates
Anhydrous Citric AcidANHYDROUS CITRIC ACIDXF417D3PSLSPRAY / TOPICAL0.01 %w/wExact identifier — unii candidate
61 equally ranked IID candidates
FD&C Blue No. 1FD&C BLUE NO. 1H3R47K3TBDSYRUP / ORAL0.05 mg/5mlExact identifier — unii candidate
37 equally ranked IID candidates
Anhydrous Citric AcidANHYDROUS CITRIC ACIDXF417D3PSLOIL / TOPICAL2 mgExact identifier — unii candidate
61 equally ranked IID candidates
GlycerinGLYCERINPDC6A3C0OXSOLUTION / DENTAL15 %w/vExact identifier — unii candidate
75 equally ranked IID candidates
Propylene GlycolPROPYLENE GLYCOL6DC9Q167V3CLOTH / TOPICAL0.03 mg/mgExact identifier — unii candidate
81 equally ranked IID candidates
SucroseSUCROSEC151H8M554INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAVENOUS2000 mgExact identifier — unii candidate
48 equally ranked IID candidates
GlycerinGLYCERINPDC6A3C0OXSHAMPOO / TOPICAL5 %w/wExact identifier — unii candidate
75 equally ranked IID candidates
Trisodium Citrate DihydrateTRISODIUM CITRATE DIHYDRATEB22547B95KSPRAY, METERED / NASAL1 mgExact identifier — unii candidate
47 equally ranked IID candidates
SucroseSUCROSEC151H8M554POWDER, FOR SUSPENSION / ORAL40017 mgExact identifier — unii candidate
48 equally ranked IID candidates
MethylparabenMETHYLPARABENA2I8C7HI9TINJECTION, SUSPENSION / SUBCUTANEOUS0.16 %w/vExact identifier — unii candidate
79 equally ranked IID candidates
SorbitolSORBITOL506T60A25RGUM, CHEWING / ORAL6168 mgExact identifier — unii candidate
44 equally ranked IID candidates
MethylparabenMETHYLPARABENA2I8C7HI9TINJECTION / INTRADERMAL1 mgExact identifier — unii candidate
79 equally ranked IID candidates
GlycerinGLYCERINPDC6A3C0OXCONCENTRATE / ORAL1800 mgExact identifier — unii candidate
75 equally ranked IID candidates
Anhydrous Citric AcidANHYDROUS CITRIC ACIDXF417D3PSLSUSPENSION, EXTENDED RELEASE / ORAL62 mgExact identifier — unii candidate
61 equally ranked IID candidates
Anhydrous Citric AcidANHYDROUS CITRIC ACIDXF417D3PSLFILM, SOLUBLE / ORAL7 mgExact identifier — unii candidate
61 equally ranked IID candidates
SorbitolSORBITOL506T60A25RTABLET, FILM COATED / ORAL5 mgExact identifier — unii candidate
44 equally ranked IID candidates
Trisodium Citrate DihydrateTRISODIUM CITRATE DIHYDRATEB22547B95KSOLUTION / INTRAOCULAR27 mgExact identifier — unii candidate
47 equally ranked IID candidates
SorbitolSORBITOL506T60A25RSOLUTION/ DROPS / OPHTHALMIC0.25 %w/vExact identifier — unii candidate
44 equally ranked IID candidates
SorbitolSORBITOL506T60A25RSOLUTION / NASAL25 mg/1mlExact identifier — unii candidate
44 equally ranked IID candidates
SucroseSUCROSEC151H8M554SUPPOSITORY / RECTALNAExact identifier — unii candidate
48 equally ranked IID candidates
FD&C Blue No. 1FD&C BLUE NO. 1H3R47K3TBDSUSPENSION / ORAL1 mgExact identifier — unii candidate
37 equally ranked IID candidates
Trisodium Citrate DihydrateTRISODIUM CITRATE DIHYDRATEB22547B95KSHAMPOO / TOPICAL186 mgExact identifier — unii candidate
47 equally ranked IID candidates
MethylparabenMETHYLPARABENA2I8C7HI9TSOLUTION / RESPIRATORY (INHALATION)0.03 %w/wExact identifier — unii candidate
79 equally ranked IID candidates
GlycerinGLYCERINPDC6A3C0OXJELLY / TOPICALNAExact identifier — unii candidate
75 equally ranked IID candidates
MethylparabenMETHYLPARABENA2I8C7HI9TCAPSULE / ORAL7 mgExact identifier — unii candidate
79 equally ranked IID candidates
MethylparabenMETHYLPARABENA2I8C7HI9TINJECTION / INTRALESIONAL0.15 %w/vExact identifier — unii candidate
79 equally ranked IID candidates
D&C Yellow No. 10D&C YELLOW NO. 1035SW5USQ3GSUSPENSION / ORAL20 mg/5mlExact identifier — unii candidate
31 equally ranked IID candidates
Propylene GlycolPROPYLENE GLYCOL6DC9Q167V3FILM, EXTENDED RELEASE / TRANSDERMAL58.13 mgExact identifier — unii candidate
81 equally ranked IID candidates
Anhydrous Citric AcidANHYDROUS CITRIC ACIDXF417D3PSLINJECTION / INFILTRATION0.02 %w/vExact identifier — unii candidate
61 equally ranked IID candidates
GlycerinGLYCERINPDC6A3C0OXSPRAY, METERED / NASAL13 mgExact identifier — unii candidate
75 equally ranked IID candidates
Propylene GlycolPROPYLENE GLYCOL6DC9Q167V3SOLUTION/ DROPS / OPHTHALMIC0.75 %w/vExact identifier — unii candidate
81 equally ranked IID candidates
SucroseSUCROSEC151H8M554GRANULE, FOR SUSPENSION / ORAL31885 mgExact identifier — unii candidate
48 equally ranked IID candidates
FD&C Blue No. 1FD&C BLUE NO. 1H3R47K3TBDLIQUID / TOPICALNAExact identifier — unii candidate
37 equally ranked IID candidates
FD&C Blue No. 1FD&C BLUE NO. 1H3R47K3TBDCONCENTRATE / ORALNAExact identifier — unii candidate
37 equally ranked IID candidates
MethylparabenMETHYLPARABENA2I8C7HI9TSYSTEM / TOPICAL42 mgExact identifier — unii candidate
79 equally ranked IID candidates
GlycerinGLYCERINPDC6A3C0OXSOLUTION / TOPICAL1971 mgExact identifier — unii candidate
75 equally ranked IID candidates
Trisodium Citrate DihydrateTRISODIUM CITRATE DIHYDRATEB22547B95KSUSPENSION, EXTENDED RELEASE / ORAL9 mgExact identifier — unii candidate
47 equally ranked IID candidates
Anhydrous Citric AcidANHYDROUS CITRIC ACIDXF417D3PSLFILM / BUCCAL9 mgExact identifier — unii candidate
61 equally ranked IID candidates
Propylene GlycolPROPYLENE GLYCOL6DC9Q167V3AEROSOL, FOAM / RECTAL1214 mgExact identifier — unii candidate
81 equally ranked IID candidates
SucroseSUCROSEC151H8M554TABLET / BUCCAL109 mgExact identifier — unii candidate
48 equally ranked IID candidates
FD&C Blue No. 1FD&C BLUE NO. 1H3R47K3TBDMOUTHWASH / BUCCALNAExact identifier — unii candidate
37 equally ranked IID candidates
Anhydrous Citric AcidANHYDROUS CITRIC ACIDXF417D3PSLGRANULE, FOR SUSPENSION / ORAL30 mgExact identifier — unii candidate
61 equally ranked IID candidates
Anhydrous Citric AcidANHYDROUS CITRIC ACIDXF417D3PSLSYRUP / ORAL268 mgExact identifier — unii candidate
61 equally ranked IID candidates
Propylene GlycolPROPYLENE GLYCOL6DC9Q167V3GEL / RECTAL3315 mgExact identifier — unii candidate
81 equally ranked IID candidates
MethylparabenMETHYLPARABENA2I8C7HI9TSUSPENSION / AURICULAR (OTIC)NAExact identifier — unii candidate
79 equally ranked IID candidates
Anhydrous Citric AcidANHYDROUS CITRIC ACIDXF417D3PSLINJECTION, POWDER, FOR SOLUTION / INTRAVENOUS35 mgExact identifier — unii candidate
61 equally ranked IID candidates
MethylparabenMETHYLPARABENA2I8C7HI9TSUPPOSITORY / VAGINALNAExact identifier — unii candidate
79 equally ranked IID candidates

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A074868-001OXYBUTYNIN CHLORIDEOXYBUTYNIN CHLORIDE5MG/5MLSYRUP / ORAL1997-02-12

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08A074868-001OXYBUTYNIN CHLORIDE5MG/5MLSYRUP / ORAL1997-02-1284e616aacf4f…
2026-08-18 06:07:402026-07A074868-001OXYBUTYNIN CHLORIDE5MG/5MLSYRUP / ORAL1997-02-12caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A074868-001OXYBUTYNIN CHLORIDE5MG/5MLSYRUP / ORAL1997-02-12011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A074868-001OXYBUTYNIN CHLORIDE5MG/5MLSYRUP / ORAL1997-02-1231067a03dcf5…
2025-08-23 18:47 UTC2025-08A074868-001OXYBUTYNIN CHLORIDE5MG/5MLSYRUP / ORAL1997-02-126a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A074868-001OXYBUTYNIN CHLORIDE5MG/5MLSYRUP / ORAL1997-02-12fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A074868-001OXYBUTYNIN CHLORIDE5MG/5MLSYRUP / ORAL1997-02-12b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A074868-001OXYBUTYNIN CHLORIDE5MG/5MLSYRUP / ORAL1997-02-1203ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A074868-001OXYBUTYNIN CHLORIDE5MG/5MLSYRUP / ORAL1997-02-122680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A074868-001OXYBUTYNIN CHLORIDE5MG/5MLSYRUP / ORAL1997-02-125bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A074868-001OXYBUTYNIN CHLORIDE5MG/5MLSYRUP / ORAL1997-02-12d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A074868-001OXYBUTYNIN CHLORIDE5MG/5MLSYRUP / ORAL1997-02-12d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A074868-001OXYBUTYNIN CHLORIDE5MG/5MLSYRUP / ORAL1997-02-1279d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A074868-001OXYBUTYNIN CHLORIDE5MG/5MLSYRUP / ORAL1997-02-12301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A074868-001OXYBUTYNIN CHLORIDE5MG/5MLSYRUP / ORAL1997-02-121e350fbaab3a…
2024-05-31 18:47 UTC2024-05A074868-001OXYBUTYNIN CHLORIDE5MG/5MLSYRUP / ORAL1997-02-128072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A074868-001OXYBUTYNIN CHLORIDE5MG/5MLSYRUP / ORAL1997-02-125c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A074868-001OXYBUTYNIN CHLORIDE5MG/5MLSYRUP / ORAL1997-02-125d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A074868-001OXYBUTYNIN CHLORIDE5MG/5MLSYRUP / ORALAARS1997-02-124b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A074868-001OXYBUTYNIN CHLORIDE5MG/5MLSYRUP / ORALAARS1997-02-1274a2ff9319b5…
2022-03-09 01:35 UTC2022-03A074868-001OXYBUTYNIN CHLORIDE5MG/5MLSYRUP / ORALAARS1997-02-12bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A074868-001OXYBUTYNIN CHLORIDE5MG/5MLSYRUP / ORALAARS1997-02-12782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A074868-001OXYBUTYNIN CHLORIDE5MG/5MLSYRUP / ORALAARS1997-02-1287673890dc5c…
2021-03-12 10:30 UTC2021-03A074868-001OXYBUTYNIN CHLORIDE5MG/5MLSYRUP / ORALAARS1997-02-125aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A074868-001OXYBUTYNIN CHLORIDE5MG/5MLSYRUP / ORALAARS1997-02-128869cabd3fbd…
2020-11-12 02:37 UTC2020-11A074868-001OXYBUTYNIN CHLORIDE5MG/5MLSYRUP / ORALAARS1997-02-12c0c555d07b60…
2019-12-14 00:12 UTC2019-12A074868-001OXYBUTYNIN CHLORIDE5MG/5MLSYRUP / ORALAARS1997-02-123f01610625f2…
2019-09-15 20:21 UTC2019-09A074868-001OXYBUTYNIN CHLORIDE5MG/5MLSYRUP / ORALAARS1997-02-12b00525d2431f…
2019-07-19 19:46 UTC2019-07A074868-001OXYBUTYNIN CHLORIDE5MG/5MLSYRUP / ORALAARS1997-02-12ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A074868-001OXYBUTYNIN CHLORIDE5MG/5MLSYRUP / ORAL1997-02-126a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A074868-001OXYBUTYNIN CHLORIDE5MG/5MLSYRUP / ORAL1997-02-121c564ffb4f44…
2023-12-20 04:57 UTC2023-12A074868-001OXYBUTYNIN CHLORIDE5MG/5MLSYRUP / ORAL1997-02-12ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A074868-001OXYBUTYNIN CHLORIDE5MG/5MLSYRUP / ORAL1997-02-12a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A074868-001OXYBUTYNIN CHLORIDE5MG/5MLSYRUP / ORAL1997-02-129b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A074868-001OXYBUTYNIN CHLORIDE5MG/5MLSYRUP / ORAL1997-02-12a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A074868-001OXYBUTYNIN CHLORIDE5MG/5MLSYRUP / ORAL1997-02-123f0d92c62455…
2023-05-13 08:27 UTC2023-05A074868-001OXYBUTYNIN CHLORIDE5MG/5MLSYRUP / ORAL1997-02-12053a50430f4f…
2023-01-26 05:58 UTC2023-01A074868-001OXYBUTYNIN CHLORIDE5MG/5MLSYRUP / ORAL1997-02-123bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A074868-001OXYBUTYNIN CHLORIDE5MG/5MLSYRUP / ORAL1997-02-123a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A074868-001OXYBUTYNIN CHLORIDE5MG/5MLSYRUP / ORAL1997-02-12f41ea6bd6efb…

Observed Orange Book normalized TE history#

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2022-04-04 05:41 UTC2022-04A074868-001AA14b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A074868-001AA174a2ff9319b5…
2022-03-09 01:35 UTC2022-03A074868-001AA1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A074868-001AA1782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A074868-001AA187673890dc5c…
2021-03-12 10:30 UTC2021-03A074868-001AA15aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A074868-001AA18869cabd3fbd…
2020-11-12 02:37 UTC2020-11A074868-001AA1c0c555d07b60…
2019-12-14 00:12 UTC2019-12A074868-001AA13f01610625f2…
2019-09-15 20:21 UTC2019-09A074868-001AA1b00525d2431f…
2019-07-19 19:46 UTC2019-07A074868-001AA1ea99ee380514…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
45baa744-e3f5-3a4e-e063-6294a90ad3f317d61203-a462-4393-b261-72bf48d519422025-12-11Warnings, Adverse reactionsExact identifier
spl set id: 17d61203-a462-4393-b261-72bf48d51942

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.